FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a tablet and a method for preparing the same, wherein the atorvastatin granules are adjusted to have a given particle size distribution value or greater than it, thereby significantly improving the tabletting characteristics in the tabletting process with fimasartan, which allows to achieve a very high homogeneity of the composition of the tablet and allows cost-effective and easily technologically feasible mass production of these tablets.
EFFECT: obtaining a tablet.
16 cl, 5 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TABLET AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2697660C2 |
| PHARMACEUTICAL PREPARATION | 2019 |
|
RU2756452C1 |
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FIMASARTAN AND HYDROCHLOROTHIAZIDE | 2013 |
|
RU2613900C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC NEPHROPATHY | 2016 |
|
RU2702117C1 |
| PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
| PHARMACEUTICAL COMBINATION FORMULATION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2014 |
|
RU2660586C1 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| PHARMACEUTICAL MEDICAL FORM OF ATORVASTATIN | 2005 |
|
RU2395280C2 |
| COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | 2014 |
|
RU2683937C2 |
